Want to see JP:4598 full AI Analyst Report?
4598 Stock Chart & Stats
¥106.00
-¥3.00(-2.88%)
At close: 4:00 PM EDT
¥106.00
-¥3.00(-2.88%)
Day’s Range― - ―
52-Week Range¥68.00 - ¥700.00
Previous CloseN/A
Volume217.10K
Average Volume (3M)414.66K
Market Cap
¥1.39B
Enterprise Value¥1.72B
Total Cash (Recent Filing)¥83.33M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-135.25
Shares Outstanding19,285,000
10 Day Avg. Volume551,350
30 Day Avg. Volume414,656
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)66.43
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt reduces interest obligations and refinancing exposure, giving the company greater flexibility than a similarly loss-making business with leverage. Although liquidity is under pressure, avoiding debt-related claims preserves some strategic options if funding or operating conditions improve.
Reported EPS GrowthReported EPS growth provides a limited positive signal that per-share performance has improved on the measured basis, even though the company remains loss-making. If this improvement persists, it could indicate progress toward stabilizing profitability and reducing the scale of future losses.
Remaining Capital BaseThe company retains positive equity and assets in FY2026, meaning it has not yet exhausted its capital base despite substantial deterioration. This remaining capitalization provides some foundation for continuing operations, although its small scale limits the protection it offers.
Bears Say
Revenue Has Fallen To ZeroRevenue remaining at zero for four reported fiscal years indicates a severe and persistent failure to convert the business into an operating revenue stream. Without renewed sales, the company lacks an internal source of funding and remains dependent on capital support.
Persistent And Worsening LossesLarge losses that have worsened over time show that profitability is not merely temporarily compressed. Continued negative earnings consume the capital base, reduce financial resilience, and make a sustainable self-funded operating model difficult to establish over the coming quarters.
Severe Ongoing Cash BurnPersistent negative operating and free cash flow demonstrates that the company is consuming cash rather than generating it from operations. The scale of FY2026 outflows, combined with a shrinking balance-sheet cushion, heightens dependence on external funding and raises continuity risk.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥68.00 and its highest was ¥700.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥1.39B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is Nov 13, 2026 which is in 13 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on Aug 07, 2026. The company reported -¥30.23 earnings per share for the quarter.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 19,285,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥30.23 in its last earnings report. Following the earnings report the stock price went down -0.926%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.